Chemotherapy Response in Glioma Patients
Author Information
Author(s): D.G.T. Thomas, J.L. Darling, E.A. Paul, T.J. Mott, J.N. Godlee, J.S. TobiaS, L.G. Capra, C.D. Collins, C. Mooney, T. Bozek, G.P. Finn, S.O. Arigbabul, D.E. Bullard, N. Shannon, R.I. Freshney
Primary Institution: Institute of Neurology, Queen Square, London
Hypothesis
Is there a relationship between in vitro chemosensitivity and relapse-free interval in patients with malignant cerebral glioma?
Conclusion
Patients with chemosensitive tumors in vitro had significantly longer relapse-free intervals compared to those who were not sensitive.
Supporting Evidence
- 55% of patients responded to PCB and/or CCNU in vitro.
- Grade III tumors were more sensitive in vitro than grade IV tumors.
- Patients with chemosensitive tumors tended to be younger.
Takeaway
This study found that some patients with brain tumors respond better to certain chemotherapy drugs, which helps them stay healthier for longer.
Methodology
Patients were treated with chemotherapy after surgery, and their tumor cells were tested for sensitivity to drugs in vitro.
Potential Biases
Potential bias due to the non-random selection of patients for testing.
Limitations
The study was retrospective and did not influence treatment based on assay results.
Participant Demographics
Patients with malignant gliomas, including both grade III and IV tumors.
Statistical Information
P-Value
0.02 for PCB, 0.01 for CCNU, 0.5 for VCR
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website